
In a strong rebuttal to concerns over pharmaceutical innovation, billionaire Mark Cuban, co-founder of Cost Plus Drugs and Shark Tank fame, argued that slashing pharmacy benefit manager (PBM) fees could paradoxically increase research and development (R&D) funding by allowing manufacturers to earn more.
What Happened: Cuban asserts that brands can earn more by selling directly to his cost-plus model, bypassing the “insane fees” and rebates charged by PBMs.